FDA: Risk of LAAO Implant-Related Adverse Events May Be Higher for Women
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Thromboembolic Disorders
Study Shows Similar Safety Profile With Rivaroxaban vs ASA After Fontan Procedure
The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure.
FDA: New Warnings and Limitations Set for Certain JAK Inhibitors
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
Pradaxa Approved to Treat, Prevent VTE in Pediatric Patients
Pradaxa oral pellets are supplied in child-resistant packets in 20mg, 30mg, 40mg, 50mg, 110mg, and 150mg dosage strengths.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
- Loading...
Loading...
Loading... 
Loading...